K-134, a Phosphodiesterase 3 Inhibitor, Prevents Brain Damage by Inhibiting Thrombus Formation in a Rat Cerebral Infarction Model

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Yoshida, Hideo ^a   Ashikawa, Yuka ^a   Itoh, Shinsuke ^a   Nakagawa, Takashi ^a   Asanuma, Akimune ^a   Tanabe, Sohei ^a   Inoue, Yoshihiro ^b   Hidaka, Hiroyoshi ^b  

^a KOWA COMPANY LTD   (Japan)

^b D Western Therapeutics Institute Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; K 134; PHOSPHODIESTERASE III INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTITHROMBOTIC ACTIVITY; ARTICLE; BRAIN DAMAGE; BRAIN INFARCTION SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; EX VIVO STUDY; IN VITRO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; RAT; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; BRAIN; CEREBRAL INFARCTION; MALE; MICE; MICE, INBRED ICR; PHOSPHODIESTERASE 3 INHIBITORS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS; UREA;

EID: 84867854229     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046432     Document Type: Article

References (22)

1. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P, (2004) Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (3 Suppl):: 483S-512S.
2. Steg PG, Dorman SH, Amarenco P, (2011) Atherothrombosis and the role of antiplatelet therapy. J Thromb Haemost 9 Suppl 1: 325-332.
3. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, et al. (2011) Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 42: 227-276.
4. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, et al. (2010) CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9: 959-968.
5. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, et al. (2000) Potent effects of novel antiplatelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59: 347-356.
6. Yoshida H, Okamura Y, Watanabe N, Ikeda Y, Handa M, (2011) Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation. Thromb Haemost 105: 487-495.
7. Honda F, Imai H, Ishikawa M, Kubota C, Shimizu T, et al. (2006) Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. Stroke 37: 223-228.
8. Ito H, Hashimoto A, Matsumoto Y, Yao H, Miyakoda G, (2010) Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. J Cereb Blood Flow Metab 30: 343-351.
9. Watson BD, Dietrich WD, Prado R, Ginsberg MD, (1987) Argon laser-induced arterial photothrombosis. Characterization and possible application to therapy of arteriovenous malformations. J Neurosurg 66: 748-754.
10. Umemura K, Ishihara H, Nakashima M, (1995) Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Thromb Res 80: 209-216.
11. Yoshida H, Itoh S, Hara T, Sasaki Y, Kondo S, et al. (2012) A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease. Atherosclerosis 221: 84-90.
12. Keravis T, Lugnier C, (2012) Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 165: 1288-1305.
13. Sasaki Y, Suzuki H, Itoh S, Yoshida H, Kondo S, et al. (2012) K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models. Eur J Pharmacol 689: 132-138.
14. Brass EP, Cooper LT, Morgan RE, Hiatt WR, (2012) A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg 55: 381-389.
15. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, et al. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33 Suppl 1: S1-S75.
16. Furie B, Furie BC, (2005) Thrombus formation in vivo. J Clin Invest 115: 3355-3362.
17. Umemura K, Kawai H, Ishihara H, Nakashima M, (1995) Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat. Jpn J Pharmacol 67: 253-258.
18. Bailey EL, Smith C, Sudlow CL, Wardlaw JM, (2011) Is the spontaneously hypertensive stroke prone rat a pertinent model of sub cortical ischemic stroke? A systematic review. Int J Stroke 6: 434-444.
19. Okuda Y, Kimura Y, Yamashita K, (1993) Cilostazol. Cardiovasc Drug Rev 11: 451-465.
20. Bramer SL, Forbes WP, Mallikaarjun S, (1999) Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 37 Suppl 2: 1-11.
21. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, et al. (2011) Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42: 517-584.
22. Hart RG, Pearce LA, Aguilar MI, (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146: 857-867.